Alnylam Pharmaceuticals Inc. (ALNY) and Global Blood Therapeutics Inc. (NASDAQ:GBT) Contrasting side by side

We will be comparing the differences between Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) and Global Blood Therapeutics Inc. (NASDAQ:GBT) as far as analyst recommendations, profitability, institutional ownership, risk, dividends, earnings and valuation are concerned. The two businesses are rivals in the Biotechnology industry.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Alnylam Pharmaceuticals Inc. 79 88.06 N/A -7.88 0.00
Global Blood Therapeutics Inc. 55 0.00 N/A -3.41 0.00

We can see in table 1 the earnings per share (EPS), gross revenue and valuation of Alnylam Pharmaceuticals Inc. and Global Blood Therapeutics Inc.


Table 2 represents Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) and Global Blood Therapeutics Inc. (NASDAQ:GBT)’s return on assets, return on equity and net margins.

Net Margins Return on Equity Return on Assets
Alnylam Pharmaceuticals Inc. 0.00% -53.9% -45.5%
Global Blood Therapeutics Inc. 0.00% -34.5% -31.8%

Risk and Volatility

Alnylam Pharmaceuticals Inc.’s 2.44 beta indicates that its volatility is 144.00% more volatile than that of Standard and Poor’s 500. Global Blood Therapeutics Inc. has a 1.51 beta and it is 51.00% more volatile than Standard and Poor’s 500.


Alnylam Pharmaceuticals Inc.’s Current Ratio is 9.3 while its Quick Ratio is 9.1. On the competitive side is, Global Blood Therapeutics Inc. which has a 14.5 Current Ratio and a 14.5 Quick Ratio. Global Blood Therapeutics Inc. is better positioned to pay off short and long-term obligations compared to Alnylam Pharmaceuticals Inc.

Analyst Recommendations

Alnylam Pharmaceuticals Inc. and Global Blood Therapeutics Inc. Recommendations and Ratings are available in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Alnylam Pharmaceuticals Inc. 0 2 6 2.75
Global Blood Therapeutics Inc. 0 0 1 3.00

$117.89 is Alnylam Pharmaceuticals Inc.’s consensus target price while its potential upside is 47.25%. On the other hand, Global Blood Therapeutics Inc.’s potential upside is 86.99% and its consensus target price is $96. The information presented earlier suggests that Global Blood Therapeutics Inc. looks more robust than Alnylam Pharmaceuticals Inc. as far as analyst belief.

Institutional & Insider Ownership

Institutional investors owned 89.2% of Alnylam Pharmaceuticals Inc. shares and 99.2% of Global Blood Therapeutics Inc. shares. Insiders owned 0.5% of Alnylam Pharmaceuticals Inc. shares. Comparatively, insiders own roughly 4.2% of Global Blood Therapeutics Inc.’s shares.


In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Alnylam Pharmaceuticals Inc. 1.45% 7.75% -6.55% -5.03% -19.85% 6.42%
Global Blood Therapeutics Inc. -4.23% 1.61% 2.54% 15.42% 35.48% 33.5%

For the past year Alnylam Pharmaceuticals Inc.’s stock price has smaller growth than Global Blood Therapeutics Inc.


On 7 of the 9 factors Global Blood Therapeutics Inc. beats Alnylam Pharmaceuticals Inc.

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference. Its pipeline of investigational RNAi therapeutics is focused on genetic medicines, cardio-metabolic diseases, and hepatic infectious diseases. The companyÂ’s clinical development programs include Patisiran, which is in Phase III clinical trial for the treatment of transthyretin-mediated amyloidosis (ATTR); Fitusiran, an investigational RNAi therapeutic that is in Phase I/II clinical trial for the treatment of hemophilia and rare bleeding disorders; and Inclisiran (ALN-PCSsc), which is in Phase II clinical trial for hypercholesterolemia. Its early stage clinical programs include Givosiran that is in Phase I trial to treat acute hepatic porphyrias; ALN-CC5 for the treatment of complement-mediated diseases; ALN-GO1 to treat primary hyperoxaluria 1; ALN-TTRsc02, an investigational RNAi therapeutic targeting TTR for the treatment of various forms of ATTR amyloidosis; and ALN-HBV for the treatment of Hepatitis B virus. The company has strategic alliances and collaboration agreements primarily with Sanofi Genzyme; The Medicines Company; Monsanto Company; Takeda Pharmaceutical Company Limited; Ionis Pharmaceuticals, Inc.; The University of British Columbia; and Acuitas Therapeutics Inc.; and Arbutus Biopharma Corporation. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.